Brief: Sanofi's Cenrifki Recommended For EU Approval Against Secondary Progressive Multiple Sclerosis Without Relapses
24/04/2026 11:11
April 24 (Reuters) - Sanofi SA SASY.PA: SANOFI’S CENRIFKI (TOLEBRUTINIB) RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS WITHOUT RELAPSES CHMP OPINION BASED ON HERCULES, GEMINI 1 AND 2 PHASE 3 STUDIES Source text: ID:nGNE4V3DGt Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes